Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 5:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 128 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Limb Deformities Congenital Clear all
Active, not recruiting Phase 2 Interventional

Study of BBP-418 in Patients With LGMD2I

NCT04800874
View directory record Official record
Conditions
LGMD2I
Interventions
BBP-418
Drug
Lead sponsor
ML Bio Solutions, Inc.
Industry
Eligibility
12 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 4, 2026, 5:53 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration

NCT05253807
View directory record Official record
Conditions
Non-Small Cell Lung Cancer (NSCLC)
Interventions
Pemigatinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 99 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
7
States / cities
Los Angeles, California • Fort Myers, Florida • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 4, 2026, 5:53 PM EDT
Completed Phase 4 Interventional Results available

Assessment of Gait After Dysport Treatment

NCT03501043
View directory record Official record
Conditions
Equinovarus; Acquired
Interventions
Dysport
Drug
Lead sponsor
Albert Einstein Healthcare Network
Other
Eligibility
18 Years to 100 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Elkins Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 4, 2026, 5:53 PM EDT
Completed No phase listed Observational

Phenotype and Etiology of Pallister-Hall Syndrome

NCT00001404
View directory record Official record
Conditions
Malformations, Multiple Abnormalies, Polydactyly
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
Not listed
Enrollment
1,170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2016
U.S. locations
3
States / cities
Los Angeles, California • Bethesda, Maryland • Greenwood, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Oct 4, 2026, 5:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Influence of Endothelial Function on Central and Peripheral Causes Of Exercise Impairment in Type 2 Diabetes

NCT00786019
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Exercise program, Ascorbic Acid (Vitamin C)
Behavioral · Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
30 Years to 55 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 12, 2023 · Synced Oct 4, 2026, 5:53 PM EDT
Recruiting No phase listed Observational

Prospective Evaluation of Treatment for Clubfoot

NCT02257229
View directory record Official record
Conditions
Clubfoot Deformity
Interventions
Surgical, Non-Surgical, Non-surgical + surgical
Procedure
Lead sponsor
Texas Scottish Rite Hospital for Children
Other
Eligibility
Up to 18 Years
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2029
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Oct 4, 2026, 5:53 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluate Safety and Biological Activity of ATYR1940 in Participants With Limb Girdle Muscular Dystrophy 2B (LGMD2B) and Facioscapulohumeral Muscular Dystrophy (FSHD)

NCT02579239
View directory record Official record
Conditions
Limb-Girdle Muscular Dystrophies, Facioscapulohumeral Muscular Dystrophy
Interventions
ATYR1940, Placebo
Biological
Lead sponsor
aTyr Pharma, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Irvine, California • Baltimore, Maryland • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 19, 2023 · Synced Oct 4, 2026, 5:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Moisture Management Liner Effectiveness Study

NCT04427007
View directory record Official record
Conditions
Amputation Stumps, Amputees, Amputation, Lower Limb Deformities, Congenital, Prosthesis User, Prosthesis
Interventions
Moisture Management Liner, Control Liner
Device
Lead sponsor
Liberating Technologies, Inc.
Industry
Eligibility
18 Years to 89 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Holliston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 11, 2025 · Synced Oct 4, 2026, 5:53 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma

NCT04604132
View directory record Official record
Conditions
Gastric Adenocarcinoma
Interventions
Derazantinib, Derazantinib-paclitaxel-ramucirumab combination
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Orlando, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 4, 2026, 5:53 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia

NCT06164951
View directory record Official record
Conditions
Achondroplasia
Interventions
Infigratinib 0.25 mg/kg/day, Placebo Comparator 0.25 mg/kg/day
Drug
Lead sponsor
QED Therapeutics, a BridgeBio company
Industry
Eligibility
3 Years to 17 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
San Francisco, California • Aurora, Colorado • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 4, 2026, 5:53 PM EDT
Completed No phase listed Observational

Cardiac Outcome Measures in Children With Muscular Dystrophy

NCT01066455
View directory record Official record
Conditions
Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Limb Girdle Muscular Dystrophy
Interventions
Not listed
Lead sponsor
Cooperative International Neuromuscular Research Group
Network
Eligibility
8 Years to 18 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
Sacramento, California • Washington D.C., District of Columbia • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2013 · Synced Oct 4, 2026, 5:53 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Participants With Limb Girdle and Facioscapulohumeral Muscular Dystrophy (FSHD)

NCT02836418
View directory record Official record
Conditions
Facioscapulohumeral Muscular Dystrophy, Limb Girdle Muscular Dystrophy
Interventions
ATYR1940
Drug
Lead sponsor
aTyr Pharma, Inc.
Industry
Eligibility
16 Years to 25 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
Irvine, California • Stanford, California • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 22, 2023 · Synced Oct 4, 2026, 5:53 PM EDT
Completed Phase 2 Interventional Results available

Weekly Steroids in Muscular Dystrophy

NCT04054375
View directory record Official record
Conditions
Limb-girdle Muscular Dystrophy, Becker Muscular Dystrophy
Interventions
Prednisone
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 4, 2026, 5:53 PM EDT
Recruiting No phase listed Observational

Prospective Clinical Assessment Study in Children With Hypochondroplasia

NCT06410976
View directory record Official record
Conditions
Hypochondroplasia
Interventions
Not listed
Lead sponsor
QED Therapeutics, a BridgeBio company
Industry
Eligibility
30 Months to 16 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
8
States / cities
Oakland, California • Aurora, Colorado • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 4, 2026, 5:53 PM EDT
Completed No phase listed Observational

Defining Clinical Endpoints in Limb Girdle Muscular Dystrophy (LGMD)

NCT03981289
View directory record Official record
Conditions
Limb Girdle Muscular Dystrophy, Muscular Dystrophies
Interventions
Not listed
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
4 Years to 65 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
9
States / cities
Irvine, California • Aurora, Colorado • Iowa City, Iowa + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 4, 2026, 5:53 PM EDT
Completed Phase 1Phase 2 Interventional

Study Evaluating MYO-029 in Adult Muscular Dystrophy

NCT00104078
View directory record Official record
Conditions
Becker Muscular Dystrophy, Facioscapulohumeral Muscular Dystrophy, Limb-Girdle Muscular Dystrophy
Interventions
MYO-029
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
9
States / cities
Washington D.C., District of Columbia • Kansas City, Kansas • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2007 · Synced Oct 4, 2026, 5:53 PM EDT
Recruiting Not applicable Interventional

Measuring Impact of Computer Gaming on Arm Use in Rett Syndrome

NCT05012475
View directory record Official record
Conditions
Rett Syndrome
Interventions
Modified Virtual Reality Gaming
Behavioral
Lead sponsor
Georgetown University
Other
Eligibility
4 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Oct 4, 2026, 5:53 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)

NCT02924376
View directory record Official record
Conditions
Cholangiocarcinoma
Interventions
Pemigatinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
49
States / cities
Anchorage, Alaska • Phoenix, Arizona • Tempe, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Oct 4, 2026, 5:53 PM EDT
Completed No phase listed Observational

Genetic Analysis of Fraser Syndrome and Fryns Syndrome

NCT00032877
View directory record Official record
Conditions
Fraser Syndrome, Fryns Syndrome, Chromosomal Abnormalities, Abnormalities, Multiple
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
Not listed
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 4, 2026, 5:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Weightbearing Assessment of Tarsal Instability

NCT01868789
View directory record Official record
Conditions
Adult-acquired Flatfoot Disorder (AAFD)
Interventions
Weightbearing CT
Radiation
Lead sponsor
Orthopedic Foot and Ankle Center, Ohio
Other
Eligibility
18 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Westerville, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 1, 2018 · Synced Oct 4, 2026, 5:53 PM EDT
Terminated Phase 1Phase 2 Interventional

Gene Delivery Clinical Trial of SRP-9003 (Bidridistrogene Xeboparvovec) for Participants With Limb-Girdle Muscular Dystrophy, Type 2E (LGMD2E) (Beta-Sarcoglycan Deficiency)

NCT03652259
View directory record Official record
Conditions
Limb-Girdle Muscular Dystrophy, Type 2E
Interventions
SRP-9003
Genetic
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
4 Years to 15 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 4, 2026, 5:53 PM EDT
Terminated Phase 2 Interventional Results available

Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)

NCT04003610
View directory record Official record
Conditions
Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma
Interventions
Pemigatinib, Pembrolizumab, Gemcitabine, Carboplatin
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
13
States / cities
Greenbrae, California • Newark, Delaware • Marietta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 4, 2026, 5:53 PM EDT
Completed No phase listed Observational

Genetic Linkage Study of Idiopathic Talipes Equinovarus (ITEV) (Clubfoot)

NCT00474344
View directory record Official record
Conditions
Clubfoot
Interventions
Not listed
Lead sponsor
University of British Columbia
Other
Eligibility
Not listed
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 18, 2022 · Synced Oct 4, 2026, 5:53 PM EDT
Recruiting Phase 2 Interventional

Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)

NCT07169279
View directory record Official record
Conditions
Achondroplasia
Interventions
Infigratinib is provided as a single dose of minitablets for oral administration, Infigratinib is provided as sprinkle capsules for daily oral administration, Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration
Drug
Lead sponsor
QED Therapeutics, a BridgeBio company
Industry
Eligibility
0 Years to 32 Months
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
3
States / cities
Oakland, California • Baltimore, Maryland • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 4, 2026, 5:53 PM EDT